Company Profile

e-therapeutics plc is a United Kingdom-based company engaged in integrating computational power and biological data to discover life-transforming RNA interference (RNAi) medicines. The Company's technology uses computation to capture and model human biology, identify targets, and develop RNAi medicines against those targets that can be progressed to the clinic. Its HepNet platform enables the generation and analysis of biological network models, providing a mechanistic approach to drug discovery. Its RNAi platform, GalOmic, enables targeted delivery to hepatocytes in the liver and the specific silencing of disease-associated genes, identified by HepNet. The Company is progressing a pipeline of RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, hemophilia, and other undisclosed indications. Its pipeline includes ETX-312, ETX-407, ETX-148, ETX-291 and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

03-05	Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 Restore-Mash Trial Of TGM-312	CI
11-26	Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, A Novel Investigational RNAi MASH Candidate	CI
10/07/25	E-therapeutics plc De-Risks Clinical Path for Galomic Candidate ETX-312 with Positive Non-Clinical Data	CI
21/05/25	E-therapeutics plc Reports Earnings Results for the Full Year Ended January 31, 2025	CI
07/05/25	E-therapeutics plc Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH	CI
31/10/24	E-therapeutics plc Reports Earnings Results for the Half Year Ended July 31, 2024	CI
06/06/24	E-therapeutics plc Reports Earnings Results for the Full Year Ended January 31, 2024	CI

07/05/25	E-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH	GL
05/02/25	E-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025	GL
31/10/24	E-therapeutics Announces Business Updates and Interim Results	GL
16/07/24	E-therapeutics plc, Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors	EQ
16/07/24	E therapeutics : Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors	PU

06/02/25	E-therapeutics présentera des données précliniques relatives à l’ETX-148 lors de l’édition 2025 du Congrès annuel de l’EAHAD
06/02/25	E-therapeutics veröffentlicht präklinische Daten zu ETX-148 auf dem EAHAD 2025

Manager	Title	Age	Since
Ahmad Mortazavi CEO	Chief Executive Officer	55	12/10/2020
Timothy Bretherton DFI	Director of Finance/CFO	-	20/09/2023
Alan Whitmore CTO	Chief Tech/Sci/R&D Officer	-	01/02/2020

Director	Title	Age	Since
Trevor Jones CHM	Chairman	84	01/03/2021
Ahmad Mortazavi CHM	Chairman	55	01/02/2020
Michael Bretherton BRD	Director/Board Member	70	10/02/2020

e-therapeutics plc Stock London S.E.

Stocks

ETX

GB00B2823H99

Biotechnology & Medical Research

Latest news : e-therapeutics plc

Press Releases : e-therapeutics plc

News in other languages : e-therapeutics plc

Quotes and Performance

Managers and Directors : e-therapeutics plc

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
E-THERAPEUTICS PLC	-6.74%	-7.93%	-	-	101M
LONZA GROUP AG	+0.97%	-1.75%	+2.17%	+18.46%	49.74B
REVOLUTION MEDICINES, INC.	-0.30%	-2.88%	+429.29%	+521.04%	44.98B
IQVIA HOLDINGS INC.	+2.13%	+0.89%	+43.59%	+19.44%	42.52B
BEONE MEDICINES AG	+0.87%	-3.73%	+8.96%	+76.62%	40.78B
CELLTRION, INC.	-0.90%	-1.74%	+15.20%	+48.44%	32.89B
ASCENDIS PHARMA A/S	+2.71%	+6.82%	-	-	17.09B
MEDPACE HOLDINGS, INC.	+1.68%	-4.20%	+25.28%	+123.70%	16.28B
EUROFINS SCIENTIFIC SE	+1.70%	-1.75%	+12.00%	+28.50%	14.4B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.34%	-1.13%	+80.94%	+42.82%	13.48B
Average	+0.55%	-2.42%	+77.18%	+109.88%	30.24B
Weighted average by Cap.	+1.01%	-2.25%	+93.36%	+128.99%